SG Americas Securities LLC Purchases 36,570 Shares of Insulet Corporation $PODD

SG Americas Securities LLC lifted its position in shares of Insulet Corporation (NASDAQ:PODD) by 1,359.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 39,261 shares of the medical instruments supplier’s stock after purchasing an additional 36,570 shares during the period. SG Americas Securities LLC owned 0.06% of Insulet worth $11,160,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. NewEdge Advisors LLC raised its stake in Insulet by 44.8% in the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after buying an additional 64 shares during the period. Steward Partners Investment Advisory LLC lifted its position in shares of Insulet by 7.3% in the second quarter. Steward Partners Investment Advisory LLC now owns 1,127 shares of the medical instruments supplier’s stock valued at $354,000 after buying an additional 77 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Insulet during the 2nd quarter worth approximately $854,000. Advisors Asset Management Inc. acquired a new position in shares of Insulet during the 2nd quarter worth approximately $128,000. Finally, J.W. Cole Advisors Inc. acquired a new position in shares of Insulet during the 2nd quarter worth approximately $262,000.

Insider Activity at Insulet

In other Insulet news, Director Michael R. Minogue purchased 2,030 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were acquired at an average cost of $246.23 per share, with a total value of $499,846.90. Following the completion of the transaction, the director owned 17,483 shares in the company, valued at $4,304,839.09. The trade was a 13.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.39% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on PODD. BTIG Research reaffirmed a “buy” rating and set a $380.00 price target on shares of Insulet in a report on Wednesday, February 18th. Oppenheimer decreased their price objective on shares of Insulet from $365.00 to $300.00 and set an “outperform” rating on the stock in a report on Thursday, February 19th. TD Cowen lowered shares of Insulet from a “buy” rating to a “hold” rating and set a $294.00 price objective on the stock. in a research report on Monday, January 26th. Stifel Nicolaus cut their target price on shares of Insulet from $370.00 to $350.00 and set a “buy” rating for the company in a research note on Wednesday, February 4th. Finally, Citigroup reduced their target price on shares of Insulet from $345.00 to $338.00 and set a “buy” rating for the company in a report on Wednesday, March 11th. Twenty equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $354.24.

Insulet Stock Performance

PODD opened at $208.22 on Monday. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.81 and a quick ratio of 2.15. The business has a fifty day simple moving average of $245.74 and a 200 day simple moving average of $288.32. Insulet Corporation has a 1 year low of $208.14 and a 1 year high of $354.88. The company has a market capitalization of $14.66 billion, a PE ratio of 59.49, a price-to-earnings-growth ratio of 1.25 and a beta of 1.42.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The firm had revenue of $783.80 million for the quarter, compared to analysts’ expectations of $768.31 million. During the same quarter last year, the business earned $1.15 EPS. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. Research analysts expect that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.